One study examines the small molecular cardiac myosin inhibitor for safety and efficacy at 96 weeks, and another compares it ...

The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms ...

Telehealth company Caregility, hybrid cancer care company Daymark Health and virtual care company AmplifyMD also garnered funding.

Mumbai runner and cardiac survivor Nihar Mehta is all set to run the 21km at the Tata Mumbai Marathon (TMM), to support the ...

On top of performing implantable cardioverter-defibrillator (ICD) functions, the integrated device also delivered appropriate ...

Conducted across seven U.S. health systems including Duke University Health System, Cleveland Clinic, and Ascension St. Vincent, VITAL-HF enrolled 178 adults with HFrEF who were not yet optimized on ...

HearO is an artificial intelligence (AI)-backed platform that analyzes patient voice inputs from mobile phones and allows ...

Women's heart health presents unique challenges due to anatomical differences, hormonal influences, and distinct symptom ...

Get insights on the upcoming HOPE 3 phase 3 trial, key endpoints, and investment risks for CAPR. Learn what to watch in ...

A new study shows targeted training may improve heart function, even in people already at risk of heart disease.

It has been a roller coaster ride for Cytokinetics, Inc. CYTK so far in 2025. While the delay in FDA approval of its lead candidate aficamten for the treatment of patients with obstructive ...

Despite previous success in oncology, the monoclonal antibody does not improve heart failure health status or physical ...